EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Diverse Regulatory Cell Populations in Antibody Mediated Rejection

Eugenia Karulina iD, Michael Nicosia iD

Current Transplantation Reports · 06.11.2026 · 13 (1)

DOI: 10.1007/s40472-026-00537-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Transplantation Reports, online erschienen am 06.11.2026. Verfasst von Eugenia Karulina und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Columbia University, New York City, NY USA. Die Arbeit nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose of Review Antibody-mediated rejection (ABMR) is a leading cause of late graft loss, and current therapies act almost exclusively on the effector arm of the alloimmune response. This review examines three classes of regulatory cell from innate and adaptive lineages and the stages of the ABMR response at which each acts, in order to assess their potential as therapeutic targets. Recent Findings CD4⁺ Tregs constrain alloimmune priming through CTLA4 dependent costimulatory blockade, cytokine-mediated suppression, and competition for IL-2. CXCR5⁺CD8⁺ antibody-suppressor cells directly eliminate donor-reactive IgG⁺ B cells in murine models. T follicular regulatory (Tfr) cells restrain germinal center reactions and alloantibody generation, and their loss produces enhanced, more pathogenic donor-specific antibody (DSA). Notably, Tfr regulation is initiated early in T-B interactions, Tfr expansion physiologically lags that of Tfh cells, and Tfr numbers are reduced in chronic ABMR. Regulatory B cells and myeloid-derived suppressor cells remain comparatively unexplored in ABMR, and the latter carry a risk of profibrotic differentiation under chronic inflammatory conditions. Summary Regulatory cell populations act predominantly during the early phases of the alloimmune response. Their therapeutic utility in ABMR is therefore likely to be constrained by timing, and to lie in the prevention of de novo DSA rather than the reversal of established rejection.

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Columbia University, New York City, NY USA.
  • Florida Research and Innovation Center, Cleveland Clinic Research, Port St. Lucie, FL USA.

ORCID-Profile: Eugenia Karulina, Michael Nicosia

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Karulina, E., & Nicosia, M. (2026). Diverse Regulatory Cell Populations in Antibody Mediated Rejection. Current Transplantation Reports, 13(1). https://doi.org/10.1007/s40472-026-00537-4

Vancouver

Karulina E, Nicosia M. Diverse Regulatory Cell Populations in Antibody Mediated Rejection. Current Transplantation Reports. 2026;13(1). doi:10.1007/s40472-026-00537-4

BibTeX
@article{Karulina2026,
  author = {Karulina, Eugenia and Nicosia, Michael},
  title = {Diverse Regulatory Cell Populations in Antibody Mediated Rejection},
  journal = {Current Transplantation Reports},
  year = {2026},
  volume = {13},
  number = {1},
  doi = {10.1007/s40472-026-00537-4}
}
Kostenlos starten →